SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending after reports surfaced of potential foundry collaboration with Intel, sparking discussions about the implications for competition and domestic chip manufacturing. The community is weighing the potential benefits and risks of this partnership, with some questioning AMD's motives and others speculating about the broader strategic implications for the semiconductor industry. Bullish sentiment is fueled by anticipation of upcoming earnings and the stock's potential to reach new highs.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

CRML is trending amid speculation of a potential U.S. government stake in the company's Greenland rare earths mine, fueled by recent news reports. The community is discussing the potential for a short squeeze and comparing CRML to other government-backed plays. Investors are closely watching the stock's movements and anticipating further news or official confirmation.

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

SPRB is trending due to FDA breakthrough therapy designation for its Sanfilippo syndrome treatment, sparking discussions of a potential short squeeze given the stock's low float. The community is actively discussing the news, potential catalysts, and speculating on the stock's next move. Some investors believe the company is significantly undervalued relative to its cash position and pipeline.

HIVE Digital Technologies Ltd. engages in building a bridge between the digital currency and blockchain sector and traditional capital markets. It operates data centers for computing and mining cryptocurrencies, including Bitcoin and other coins. The firm owns and operates green energy-powered data center facilities in Canada, Sweden, and Iceland. Its project includes Iceland Cryptocurrency Mining. HIVE Digital Technologies was founded on June 24, 1987 and is headquartered in San Antonio, TX.

HIVE Digital Technologies Ltd.

HIVE Digital Technologies Ltd

HIVE Digital Technologies is trending as investors discuss its undervaluation compared to peers, especially regarding its Bitcoin mining and AI infrastructure. Community members are highlighting the company's increasing hash rate, efficient operations, and expansion into high-performance computing, generating optimism about revenue growth and future potential. Some are drawing comparisons to other miners like IREN and anticipating a significant price increase soon.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending, with community members frequently mentioning the ticker and engaging with the project's social media and website. Conversations highlight the community's positive vibes and the token's association with cannabis culture, drawing comparisons to Bitcoin.

Niu Technologies is a holding company, which engages in the provision of urban mobility solutions. It is involved in the design, manufacture, and sale of electric bicycles and motorcycles. Its product portfolio includes electric scooters and motorcycles, electric kick-scooters, and e-bikes. The company was founded by Wei Hua He, Yi Nan Li, Yi Lin Hu, Nelson Joseph, Cheng Dong Liu, and Yi Bong Zhang in September 2014 and is headquartered in Beijing, China.

Niu Technologies - ADR

Niu Technologies

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

Aduro Clean Technologies is trending as the company progresses toward commissioning its pilot plant in September, a key milestone for its Hydrochemolytic technology which transforms waste into valuable resources. Community members are closely watching for updates on partnerships and the potential impact of upcoming PR campaigns. Bullish sentiment is fueled by the company's expansion into new markets like synthetic turf recycling and its collaborations within the plastics industry.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

EOSE is trending due to renewed investor interest in energy storage solutions, particularly those supporting AI and data centers, with discussions highlighting the company's potential as a key player. Community members are actively discussing its American-made advantage, potential for a short squeeze, and comparing it to sector peers. Recent analyst upgrades and positive technical indicators appear to be contributing to the upward momentum.

Knightscope, Inc. engages in the provision and development of security technology solutions. Its product portfolio includes the K1 stationary machine, the K3 indoor machine, the K5 outdoor machine, and the K7 multi-terrain four-wheel vehicle. Its machines patrol client sites without the need for remote control to provide a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area, and deter crime. The company was founded by William Santana Li and Stacy Dean Stephens on April 4, 2013 and is headquartered in Sunnyvale, CA.

Knightscope Inc - Ordinary Shares - Class A

Knightscope ($KSCP) is trending due to speculation and community-driven hype, fueled by mentions of a user named 'Sophie' who is purportedly knowledgeable about the stock. Despite some skepticism and warnings of pump-and-dump characteristics, many traders are buying based on 'Sophie's' bullish outlook and potential for quick gains. The stock's low float and recent attention are contributing to its volatile price action.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's platform is reportedly experiencing downtime, sparking frustration among users who are unable to manage their positions. The community is actively discussing the app's reliability and potential impact on their investments, with some expressing intentions to switch to alternative platforms. Amidst this, some users speculate on potential partnerships with tech companies and highlight bullish sentiment related to the broader market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates

Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +4.84% and +26.21%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -100.00% and -1.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why

Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success

Shares of Lyra Therapeutics, Inc. (LYRA) rocketed 370% on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.lyratherapeutics.com/news-releases/news-release-details/lyra-therapeutics-reports-positive-results-enlighten-2-phase-3">announced</a> positive results from its late-stage clinical trial of LYR-210 in adult patients with chronic rhinosinusitis.LYR-210 is an investigational bioabsorbable nasal implant for the treatment of chronic rhinosinusitis (CRS) in patients who have failed current therapies and require further intervention.It is designed to be inserted in a simple, in-office procedure and intended to deliver six months of continuous anti-inflammatory therapy, mometasone furoate, to the sinonasal passages to treat CRS.LYR-210 demonstrated statistically significant improvement compared to sham control in key symptoms of chronic rhinosinusitis, such as nasal obstruction, nasal discharge, and facial pain/pressure at week 24 in patients with or without nasal polyps in the trial, the company said.The trial enrolled approximately 180 CRS patients who had not had prior ethmoid sinus surgery. While some received the company’s lead product, others received a sham control.The implant was well-tolerated, and most commonly reported adverse events included epistaxis, upper respiratory tract infection, chronic sinusitis, acute sinusitis, nasopharyngitis, COVID-19, and headache, the company added.Lyra said that its therapy is expected to help the estimated four million CRS patients in the United States who fail medical management each year.Lyra CEO Maria Palasis stated that the company now plans to align with the FDA on the path forward for submitting a new drug application.The company had previously conducted a late-stage study for the implant, which did not meet its goals.On Stocktwits, retail sentiment around Lyra jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:630/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_2_05_49_PM_png_c936942df7.webp" alt="LYRA's Sentiment Meter and Message Volume as of 2:05 p.m. ET on June 2, 2025 | Source: Stocktwits" width="630" height="62"><figcaption>LYRA's Sentiment Meter and Message Volume as of 2:05 p.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/LYRA">LYRA stock</a> is up by about 116% this year and by about 43% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/crowdstrike-and-microsoft-team-up-to-simplify-cyber-threat-intelligence/chkYeQARbH1">CrowdStrike And Microsoft Team Up To Simplify Cyber Threat Intelligence: Retail’s Buoyant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Lyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s Thrilled

LYR-210 demonstrated statistically significant improvement compared to sham control in key symptoms of chronic rhinosinusitis, such as nasal obstruction, nasal discharge, and facial pain/pressure at week 24. 

Equity

LYR-210 demonstrated statistically significant improvement compared to sham control in key symptoms of chronic rhinosinusitis, such as nasal obstruction, nasal discharge, and facial pain/pressure at week 24. 


Lyra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Latest Ratings for LYRA
 DateFirmActionFromTo May 2020B of A SecuritiesInitiates Coverage OnBuy May 2020JefferiesInitiates Coverage OnBuy
 View More Analyst Ratings for LYRA

 View the...

Why Lyra Therapeutics Stock Is Down 93% Today

Lyra Therapeutics shares are trading lower by 93% to $0.30 during Monday's session. The company announced the ENLIGHTEN 1 trial did not meet its primary endpoint.
read more...

The volume for Lyra Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 516% of the 65-Day Volume Moving Average

LYRA's total volume now sits at 2M. The +0.16% price change was insignificant, leaving IBM's price at $6.23...

Lyra Therapeutics (LYRA, $6.13) entered Downtrend as Momentum indicator drops below 0 level on Mar 26, 2024

This indicator may be signaling that LYRA's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

The volume for Lyra Therapeutics stock increased for three consecutive days, resulting in a record-breaking daily growth of 187% of the 65-Day Volume Moving Average

LYRA's total volume now sits at 700.8K. The +0.99% average daily price change was insignificant these 3 days, leaving LYRA's price at $6.13...

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.

Lyra Therapeutics Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$7.30
Prev Close	$7.00
Open	$7.82
Dividend Yield	0.00%
50-Day Moving Average	$6.84
Beta	-0.23
Avg. Volume	17,916.71
PE Ratio	-0.24

52-Week High	$37.50
52-Week Low	$3.81
Market Capitalization	$11.51M
EPS (Annual)	-$71.75
Price to Book	7.01
Revenue Per Employee	$51,133.33
Enterprise Value/EBITDA	N/A

LYRA
Lyra Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LYRA News

LYRA Lyra Therapeutics Inc